UK-based in-home healthcare provider Cera has secured $150 million in funding to expand its AI-driven platform, addressing gaps in a strained healthcare system.
In a landscape where public healthcare systems are under pressure, particularly in Western countries, UK-based Cera is stepping up. The company announced it has raised $150 million through a mix of debt and equity to scale its proprietary in-home healthcare platform. Although the exact breakdown remains undisclosed, the majority of the funding comes from debt.
The funding round was led by BDT & MSD Partners and Schroders Capital, with the goal of enhancing Cera’s AI capabilities. The platform integrates proprietary data modelling alongside tools from Google’s Gemini AI and Microsoft’s ChatGPT.
Cera’s technology empowers carers with an app that helps manage daily tasks and monitor patient symptoms. The platform uses AI to analyse unstructured data, such as reports of patient falls, to predict risks like illness or injury. According to the company, these predictive insights have contributed to:
- A 70% reduction in hospitalisations
- A 20% decrease in patient falls
- Faster hospital discharges, up to five times quicker
“We’ve scaled our technology significantly and expanded into more services at home,” said Dr. Ben Maruthappu, CEO and founder of Cera. “We’re now able to predict over 80% of falls a week before they occur and reduce hospitalisations by up to 70%.”
The company serves over 30 million people across the UK, employing 10,000 carers and nurses while partnering with more than 150 local governments and two-thirds of NHS Integrated Care Systems.
Cera claims its model is making a tangible impact on the NHS by reducing strain on public resources. The company also emphasises its financial health, stating it became free cash flow positive in 2024 and is increasingly self-sustaining.
Cera’s AI-led approach has earned recognition for saving the UK healthcare system an estimated £1 million daily, according to an independent analysis by consultancy Faculty.
Cera faces competition from UK-based providers like Home Instead and Bluebird Care, which rely on non-proprietary apps. In the US, similar companies include Signify Health and Honor, the latter of which has raised $625 million.
Looking ahead, Cera plans to expand its services, including nursing, physiotherapy, mental health support, and care for disabilities, solidifying its position as a comprehensive home healthcare provider.
Rob Platek, partner at BDT & MSD, commented, “Cera has achieved strong growth through its ability to leverage technology for exceptional care. We believe it is well-positioned to scale further.”
With over $407 million raised to date, Cera is now one of Europe’s largest health tech companies and continues to innovate in a sector demanding sustainable solutions.
